Is Instructure Inc (INST) A Good Stock to Buy?

As industry-wide interest jumped, key hedge funds were leading the bulls’ herd. Ardsley Partners established the most outsized position in Instructure Inc (NYSE:INST), having $5.2 million invested in the company at the end of the quarter. Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital also initiated a $1.8 million position during the quarter. The following funds were also among the new INST investors: John Overdeck and David Siegel’s Two Sigma Advisors and Frank Slattery’s Symmetry Peak Management.

Let’s now review hedge fund activity in other stocks similar to Instructure Inc (NYSE:INST). We will take a look at Albany Molecular Research, Inc. (NASDAQ:AMRI), Anika Therapeutics, Inc. (NASDAQ:ANIK), and VASCO Data Security International, Inc. (NASDAQ:VDSI). This group of stocks’ market values are closest to INST’s market value.

As you can see these stocks had an average of 14 hedge funds with bullish positions and the average amount invested in these stocks was $62 million. That figure was $32 million in INST’s case. Anika Therapeutics, Inc. (NASDAQ:ANIK) is the most popular stock in this table. On the other hand Albany Molecular Research, Inc. (NASDAQ:AMRI) is the least popular one with only 13 bullish hedge fund positions. Compared to these stocks Instructure Inc (NYSE:INST) is even less popular than AMRI. Considering that hedge funds aren’t fond of this stock in relation to other companies analyzed in this article, it may be a good idea to analyze it in detail and understand why the smart money isn’t behind this stock.

Disclosure: None